Targeted therapies against these pathways, including PI3K, AKT, MEK, and ERK inhibitors, have shown effectiveness in clinical trials for certain cancers and hold potential for improving cancer patient outcomes [34,35]. This evidence concerns the gene EPHB2 and cancer.